"Designing Growth Strategies is in our DNA"
Chronic kidney disease, also known as chronic kidney failure, defined as the gradual loss of kidney function. Kidneys filter wastes and excess fluids from blood, which are then excreted in the urine. When chronic kidney disease reaches an advanced stage, dangerous levels of fluid, electrolytes, and wastes can build up in the human body. In the early stages of chronic kidney disease, have few signs or symptoms. Chronic kidney disease is apparent until your kidney function is significantly impaired. According to the National Kidney Foundation, 10.0% of the population worldwide is affected by chronic kidney disease (CKD), and millions die each year because of less affordable treatment. The critical role of the kidneys in the maintenance of the overall health and the other comorbidities associated with chronic kidney failure is anticipated to contribute to the positive growth of the market.
The rise in the prevalence and incidence of several diseases such as diabetes, hypertension, interstitial nephritis, glomerulonephritis, polycystic kidney disease, and others are the some of the major conditions responsible for the high demand for the kidney disease treatment globally. Additionally, increasing the prevalence of kidney diseases and the rising demand for new techniques for the diagnosis of chronic diseases are some of the major factors driving the growth of the global chronic kidney disease treatment market.
To gain extensive insights into the market, Request for Customization
The high cost of treatment and the presence of generic drugs in the market by new players are some of the factors restraining the growth of the global chronic kidney disease treatment market.
Some of the major companies that are present in the global chronic kidney disease treatment market are F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., AstraZeneca plc, Pfizer, Inc., Amgen Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., Keryx Biopharmaceuticals, Inc., Allergan plc., FibroGen Inc., Johnson & Johnson, and others.
By Type of Treatment
· ACE Inhibitors
· Angiotensin-II receptor Blockers
· Calcium channel Blockers
· Erythropoiesis-stimulating Agents (ESAs)
· Transplantation of Kidneys
By End User
· Hospitals & Clinics
· Ambulatory Surgery Centres (ASCs)
· Dialysis Centres
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among the treatment type, drugs, and dialysis are projected to hold a considerable share of the global chronic kidney disease treatment market due to higher adoption of these treatment options for chronic kidney disease treatment in developed as well as developing countries.
Among the regions, North America dominated the global chronic kidney disease treatment market in 2018. According to, Centers for Disease Control and Prevention in 2017, 30 million people or 15% of U.S. adults are estimated to have chronic kidney disease. Asia Pacific is expected to grow at a significant CAGR due to the increasing number of kidney diseases registered, technological advancement in the diagnosis and treatment of the chronic kidney diseases, and initiatives taken by the government about spreading awareness about the kidney diseases symptom as well as treatment in the region. According to, Centers for Disease Control and Prevention in 2017, it is estimated that the number of cases of kidney failure will increase disproportionately in developing countries, such as China and India, where the number of elderly people is increasing, that would result in increasing demand for the chronic kidney disease treatment in the region.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry